Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: Discovery of novel allelic variants

Pharmacogenomics

Volumn 14, Issue 3, 2013, Pages 261-276

  Montané Jaime, Lazara Karelia ^a   Lalla, Anthony ^a   Steimer, Werner ^b   Gaedigk, Andrea ^c  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

allelic variation; CYP2D6; dextromethorphan; genotype; phenotype; SNP; Trinidad and Tobago

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN;

ADULT; AFRICAN AMERICAN; AFRO-TRINIDADIAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; CUBAN MESTIZO; CYP2D6 GENE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; INDIAN; INDIVIDUALIZATION; INDO-TRINIDADIAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POPULATION GENETICS; PUERTO RICAN; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE CUBAN;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; PHENOTYPE; TRINIDAD AND TOBAGO;

EID: 84873686540     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.207     Document Type: Article

References (51)

1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2005).
2. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 48(11), 689-723 (2009).
3. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 48(12), 761-804 (2009).
4. Kirchheiner J, Schmidt H, Tzvetkov et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7(4), 257-265 (2007).
5. De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47(1), 75-85 (2006).
6. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004).
7. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur. Arch. Psychiatry Clin. Neurosci. 256(5), 287-293 (2006).
8. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 23-37 (2004).
9. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11(2), 126-135 (2006).
10. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278(1), 441-446 (1996).
11. Mc Lellan RA, Oscarson M, Seidegaård, J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7(3), 187-191 (1997).
12. Bernal ML, Sinues B, Johansson I et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 9(5), 657-660 (1999).
13. Adithan C, Gerard N, Naveen AT, Koumaravelou K, Shashindran CH, Krishnamoorthy R. Genotype and allele frequency of CYP2D6 in Tamilian population. Eur. J. Clin. Pharmacol. 59(7), 517-520 (2003).
14. Naveen AT, Adithan C, Soya SS, Gerard N, Krishnamoorthy R. CYP2D6 genetic polymorphism in south Indian populations. Biol. Pharm. Bull. 29(8), 1655-1658 (2006).
15. Lamba V, Lamba JK, Dilawari JB, Kohli KK. Genetic polymorphism of CYP2D6 in north Indian subjects. Eur. J. Clin. Pharmacol. 54(9-10), 787-791 (1998).
16. Mamidi RN, Satyavageeswaran S, Vakkalanka S et al. Polymorphism of dextromethorphan oxidation in south Indian subjects. Clin. Pharmacol. Ther. 66(2), 193-200 (1999).
17. Abraham BK, Adithan C, Kiran PU, Asad M, Koumaravelou K. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India. Acta Pharmacol. Sin. 21(6), 494-498 (2000).
18. Abraham BK, Adithan C, Shashindran CH, Vasu S, Alekutty NA. Genetic polymorphism of CYP2D6 in a Keralite (south India) population. Br. J. Clin. Pharmacol. 49(3), 285-286 (2000).
19. Llerena A, Dorado P, Ramirez R. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. 12(2), 176-183 (2012).
20. Gonzales-Tejera G, Gaedigk A, Corey S. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. PR Health Sci. J. 9(3), 299-304 (2010).
21. Laurence KO. Immigration into the West Indies in the 19th Century (3rd Edition), Caribbean Universities Press, London, UK (1971).
22. Soares-Ramesar MD. Survivors of Another Crossing: a History of East Indians in Trinidad, 1880-1946. School of Continuing Studies, The University of the West Indies, St Augustine, Trinidad and Tobago (1994).
23. Maharajh HD, Abdool P, Mohammed-Emamdee R. The theory and practice of consultation-liaison (CL) psychiatry in Trinidad and Tobago with reference to suicidal behavior. Scientific World Journal 30(8), 920-928 (2008).
24. Maharajh RG. Depression and the nature of Trinidadian family practice: a cross-sectional study. BMC Fam. Pract. 8, 25 (2007).
25. Maharajh HD, Konings M. Cannabis and suicidal behavior among adolescents: a pilot study from Trinidad. Scientific World Journal. 5, 576-585 (2005).
26. Trinidad and Tobago Ministry of Health. Statistics. Presented at: the 4th Annual Breast Cancer Conference. Presented by the Minister of Health, Port of Spain, Trinidad and Tobago, 30 October 2009.
27. Rao AV, Mohammed WA, Ragoonanan C, Omo-Igbinomwanhia NE. Evaluation of oestrogen and progesterone receptors, and c-erb B-2 in carcinoma of the breast in Trinidadian women. West Indian Med. J. 51(1), 4-9 (2002).
28. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28(23), 3784-3796 (2010).
29. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in African Americans. Clin. Pharmacol. Ther. 72(1), 76-89 (2002).
30. Gaedigk A, Bradford LD, Leeder JS. Discovery of a novel non-functional cytochrome P4502D6 allele, CYP2D6*42, in African Americans. Clin. Pharmacol. Ther. 73(6), 575-576 (2003).
31. Gaedigk A, Eklund JD, Pearce RE et al. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin. Pharmacol. Ther. 81(6), 817-820 (2007).
32. Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. 64(5), 465-475 (2008).
33. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
34. Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik T, Soback S. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther. Drug Monit. 22(5), 510-516 (2000).
35. Sambroolk J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual, (Volume 1) (2nd Edition). Cold Spring Harbor Laboratory Press, NY, USA (1989).
36. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab. Disposition 34(4), 563-569 (2006).
37. Gaedigk A, Ndjountsche L, Divakaran K. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: discovery of novel gene duplications in African Americans. Clin. Pharmacol. Ther. 81(2), 242-251 (2007).
38. Gaedigk A, Jaime LK, Bertino JS. Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front. Pharmacol. 1, 121 (2010).
39. Gaedigk A, Fuhr U, Johnson C, Bérard A, Bradford LD, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11(1), 43-53 (2010).
40. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics 13(1), 91-111 (2012).
41. Steimer W, Zöpf K, von Amelunxen S et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50(9), 1623-1633 (2004).
42. Sim SC, Daly AK, Gaedigk A. CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. Pharmacogenet. Genomics 22, 692-694 (2012).
43. Hosono N, Kato M, Kiyotani K, Mushiroda T, Takata S, Sato H. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin. Chem. 55(8), 1546-1554 (2009).
44. Abduljalil K, Frank D, Gaedigk A et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin. Pharmacol. Ther. 88(5), 643-651 (2010).
45. Rouse I. The Tainos: Rise & Decline of the People Who Greeted Columbus. Yale University Press, CT, USA (1993).
46. Sachse C, Brockmöller J, Bauer S, Roots I.Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997).
47. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12(5), 375-383 (2002).
48. Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur. J. Clin. Pharmacol. 68(5), 637-644 (2012).
49. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin. Pharmacol. Toxicol. 100(1), 23-30 (2007).
50. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol. 63(4), 321-333 (2007).
51. Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab. Dispos. 33(7), 1052-1055 (2005).